Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 10

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 10
---
 may, however, receive up to approximately                
 $37 million in aggregate gross proceeds from the exercise of the Pre-Funded Warrants and the Series A Common Warrants if such warrants are exercised for cash. The Series B Common Stock Warrants are                                                     
 exercisable for cash, in which case we could receive up to approximately $55.5 million in aggregate gross proceeds, or pursuant to a zero exercise price provision, pursuant to which the Series B Common Stock Warrants can be exercised without further 
 payment to us and for three times the number of shares of common stock issuable upon exercise of the Series B Common Stock Warrants for cash. We believe it is highly unlikely that a warrant holder would exercise their Series B Common Stock Warrants  
 for cash rather than pursuant to the zero exercise price provision. To the extent that we receive any proceeds from the exercise of the Warrants, we intend to use the proceeds for general corporate purposes. See the section titled “Use of            
 Proceeds.”                                                                                                                                                                                                                                                |

| Nasdaq Symbol | “PSTV” |

| Offering price | The selling stockholders will offer the shares of common stock offered by this prospectus at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. |

| Risk factors | Any investment in our shares of common stock offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under the section entitled “Risk Factors” and elsewhere in 
 this prospectus.                                                                                                                                                                                                                  |

2

RISK FACTORS

An investment in our shares of common stock involves a high degree of risk. In addition to the risks and uncertainties discussed below, and above under
“Cautionary Note Regarding Forward-Looking Statements,” you should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and all other
information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in any applicable prospectus supplement, before making an
investment decision. Our business, prospects, financial condition or operating results could decline due to any of these risks and, as a result, you may lose all or part of your investment. The occurrence of any of these risks might cause you to
lose all or part of your investment in the offered securities. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial